Skip to main content

Be a Marine Mammal Hero

Hungry pups like elephant seal Davey are pouring through our doors. Yes, we are in the swing of pupping season, and that’s why your help is urgently needed.

What if I told you there’s a simple way you can have double the impact for good?

Today, your gift will help provide what a pup like Davey needs: double the fish meals to regain his strength for a second chance at life. How? Because your gift will be matched dollar-for-dollar up to $5,000 when you give by Sunday, June 1.

Double my impact!
Elephant seal pup, Davey
northern elephant seal Mizuna

Pharmacokinetic Study of Oral Ɛ-Aminocaproic Acid in the Northern Elephant Seal

Pharmacokinetic study of oral Ɛ-Aminocaproic acid in the Northern elephant seal (Mirounga angustirostris)
  • Lungworm
  • Pharmacokinetics

Abstract

ϵ-Aminocaproic acid (EACA) is a lysine analogue antifibrinolytic drug used to treat bleeding disorders in humans and domestic animals. Its use in zoological medicine is rare, and dosage is anecdotal. One possible application of EACA is to treat bleeding associated with prepatent Otostrongylus arteritis in Northern elephant seals (Mirounga angustirostris) presenting to wildlife rehabilitation centers. This study used an in vitro model of hyperfibrinolysis and a thromboelastograph-based assay to estimate the therapeutic plasma concentration of EACA in elephant seals (85 μg/ml, 95% confidence interval = 73.8–96.8 μg/ml). A concurrent pharmacokinetic study of orally administered, single-dose EACA found that doses of 75 and 100 mg/kg achieved therapeutic plasma concentrations (>85 μg/ml), but the drug was rapidly eliminated and remained in the therapeutic range for only 0.4 and 1.5 hr, respectively. Models of repeated oral dosing at 100 mg/kg every 6 hr predict that therapeutic plasma concentration will be maintained for 31.7% (7.6 hr) of a 24-hr period. More frequent dosing would be required to maintain continuous therapeutic concentrations but would be impractical in a wildlife rehabilitation setting. Further pharmacodynamic studies to evaluate the duration of action of EACA in elephant seals and a prospective, placebo-controlled study are needed to determine if EACA is effective in decreasing bleeding associated with prepatent Otostrongylus arteritis and other bleeding disorders in this species. 


Kaye, S., Johnson, S., Arnold, R.D., Nie, B., Davis, J.T., Gulland, F., Abou-Madi, N., Fletcher, D.J. 2016. Pharmacokinetic study of oral Ɛ-Aminocaproic acid in the Northern elephant seal (Mirounga angustirostris). Journal of Zoo and Wildlife Medicine. 47(2): 438-446.

lungworm
pharmacokinetics

Related Publications

Recent News